Montiget 10mg tablet – 10’s

Details

Montiget™ (Montelukast sodium) is a prescription pharmaceutical drug used for the long-term management of respiratory conditions. As a Leukotriene Receptor Antagonist, it works by blocking the action of leukotrienes, which are chemicals released in the body that cause the inflammation, swelling, and narrowing of airways seen in asthma and allergic reactions.

Key Ingredient and Strength

The active compound is Montelukast sodium at a strength of 10 mg per film-coated tablet.

Main Uses (Indications)

• Prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms.
• Relief of symptoms of seasonal allergic rhinitis (hay fever).
• It can also be used to prevent exercise-induced bronchoconstriction.

Usage Instructions (Itemized with Dosage/Duration)

1. Dosage: The typical dose for adults and adolescents (15 years and older) is one 10 mg tablet once daily.
2. Timing: The tablet should preferably be taken in the evening to manage nighttime asthma symptoms. For allergic rhinitis, timing can be adjusted per physician instruction.
3. Administration: Taken orally (Voie orale / For oral use) with or without food.

Potential Risks and Adverse Events

Common side effects are generally mild and include headache, stomach pain, and upper respiratory infection. Behavioral and mood changes are rare but serious side effects that must be reported to a doctor immediately, including agitation, aggression, depression, and suicidal thoughts.

Warnings/Precautions

• Acute Attacks: Montiget is for **maintenance therapy** only and should not be used to treat sudden, acute asthma attacks. Patients must continue to use their fast-acting rescue inhalers as needed.
• Prescription Required: This is a prescription-only medication; use it strictly as directed by a healthcare professional.
• Psychiatric Monitoring: Patients and caregivers should be aware of and monitor for changes in behavior and mood.

Quick Product Facts Table

Mechanism of Operation

Montelukast selectively and potently antagonizes the CysLT1 receptor. By blocking this receptor, it inhibits the actions of the inflammatory mediators (leukotrienes) that promote inflammation, edema, mucus secretion, and bronchoconstriction. This results in reduced inflammation in the airways, leading to improved airflow and a reduction in allergy symptoms.